E Fund Management Co. Ltd. Buys 771 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)

E Fund Management Co. Ltd. lifted its stake in Dynavax Technologies Co. (NASDAQ:DVAX) by 4.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 17,627 shares of the biopharmaceutical company’s stock after acquiring an additional 771 shares during the period. E Fund Management Co. Ltd.’s holdings in Dynavax Technologies were worth $225,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC raised its position in shares of Dynavax Technologies by 19.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company’s stock valued at $83,000 after purchasing an additional 1,076 shares during the period. Sanctuary Advisors LLC raised its holdings in Dynavax Technologies by 6.3% in the 4th quarter. Sanctuary Advisors LLC now owns 18,836 shares of the biopharmaceutical company’s stock worth $245,000 after acquiring an additional 1,109 shares during the period. GAMMA Investing LLC lifted its position in Dynavax Technologies by 55.1% during the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock worth $52,000 after acquiring an additional 1,457 shares during the last quarter. US Bancorp DE boosted its holdings in Dynavax Technologies by 291.4% during the third quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 2,034 shares during the period. Finally, Smartleaf Asset Management LLC grew its position in shares of Dynavax Technologies by 463.3% in the fourth quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 2,034 shares during the last quarter. 96.96% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently weighed in on DVAX shares. The Goldman Sachs Group cut Dynavax Technologies from a “neutral” rating to a “sell” rating and cut their price objective for the stock from $15.00 to $12.00 in a research report on Tuesday, February 11th. StockNews.com upgraded Dynavax Technologies from a “hold” rating to a “buy” rating in a report on Monday, February 24th. William Blair reaffirmed an “outperform” rating on shares of Dynavax Technologies in a research report on Friday, February 21st. Finally, HC Wainwright reiterated a “buy” rating and set a $31.00 target price on shares of Dynavax Technologies in a research note on Friday, February 21st.

Dynavax Technologies Trading Up 0.4 %

Dynavax Technologies stock opened at $14.40 on Monday. Dynavax Technologies Co. has a 12 month low of $9.74 and a 12 month high of $14.63. The stock has a market cap of $1.79 billion, a price-to-earnings ratio of 80.00 and a beta of 1.23. The business has a 50 day moving average price of $13.01 and a two-hundred day moving average price of $12.22. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33.

Dynavax Technologies (NASDAQ:DVAX) last issued its earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 EPS for the quarter, hitting the consensus estimate of $0.05. The firm had revenue of $72.03 million during the quarter, compared to analysts’ expectations of $72.70 million. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. As a group, equities analysts forecast that Dynavax Technologies Co. will post 0.32 EPS for the current year.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.